{"id":62396,"date":"2026-04-04T22:04:53","date_gmt":"2026-04-04T14:04:53","guid":{"rendered":"https:\/\/flcube.com\/?p=62396"},"modified":"2026-04-04T22:04:55","modified_gmt":"2026-04-04T14:04:55","slug":"shanghai-huilun-pharma-launches-hong-kong-ipo-with-integrated-pharmaceutical-platform-and-robust-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62396","title":{"rendered":"Shanghai Huilun Pharma Launches Hong Kong IPO with Integrated Pharmaceutical Platform and Robust Pipeline"},"content":{"rendered":"\n<p><strong>Shanghai Huilun Pharmaceutical Co., Ltd.<\/strong> has successfully completed its <strong>initial public offering (IPO)<\/strong> on the <strong>Hong Kong Stock Exchange<\/strong>, marking a significant milestone for the Chinese pharmaceutical company that operates an <strong>integrated, end-to-end pharmaceutical system<\/strong> spanning research and development, manufacturing, and commercialization.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-company-profile-amp-operational-framework\">Company Profile &amp; Operational Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Shanghai Huilun Pharmaceutical Co., Ltd.<\/td><\/tr><tr><td><strong>Listing Venue<\/strong><\/td><td>Hong Kong Stock Exchange<\/td><\/tr><tr><td><strong>Business Model<\/strong><\/td><td>Integrated R&amp;D, manufacturing, and commercialization<\/td><\/tr><tr><td><strong>Therapeutic Focus<\/strong><\/td><td>Immuno-inflammation, pain management, oncology, chronic diseases<\/td><\/tr><tr><td><strong>Marketed Products<\/strong><\/td><td>10+ approved products<\/td><\/tr><tr><td><strong>2025 Revenue<\/strong><\/td><td>RMB 686 million (USD 99.7 million)<\/td><\/tr><tr><td><strong>Key Commercial Products<\/strong><\/td><td>Sivelestat (Elaspol), Zuoyu (levofolinate)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-portfolio-highlights\">Commercial Portfolio Highlights<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Sivelestat (Elaspol):<\/strong> The only domestic generic version in China, representing a key revenue driver<\/li>\n\n\n\n<li><strong>Zuoyu:<\/strong> China&#8217;s first Category II generic levofolinate, demonstrating the company&#8217;s regulatory expertise<\/li>\n\n\n\n<li><strong>Revenue Foundation:<\/strong> Primary income derived from established marketed products with strong market penetration<\/li>\n\n\n\n<li><strong>Therapeutic Breadth:<\/strong> Portfolio spans critical areas including immuno-inflammation, pain management, oncology, and other chronic conditions<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-innovative-pipeline-development\">Innovative Pipeline Development<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug Class<\/th><th>Number of Candidates<\/th><th>Development Stage<\/th><\/tr><\/thead><tbody><tr><td><strong>Class I Innovative Drugs<\/strong><\/td><td>4 candidates<\/td><td>Clinical development<\/td><\/tr><tr><td><strong>Class II Improved New Drugs<\/strong><\/td><td>3 candidates<\/td><td>Clinical development<\/td><\/tr><tr><td><strong>Total Pipeline Assets<\/strong><\/td><td>7 innovative candidates<\/td><td>Active clinical programs<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The company&#8217;s pipeline demonstrates steady progress in developing novel therapeutics, with a strategic focus on both breakthrough innovations (Class I) and meaningful improvements to existing therapies (Class II).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-positioning-amp-growth-strategy\">Market Positioning &amp; Growth Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Integrated Advantage:<\/strong> End-to-end operational control enables cost efficiency, quality assurance, and rapid scale-up capabilities<\/li>\n\n\n\n<li><strong>Dual Revenue Model:<\/strong> Established commercial products provide stable cash flow while innovative pipeline offers long-term growth potential<\/li>\n\n\n\n<li><strong>Regulatory Expertise:<\/strong> Success with first-in-class generics (Zuoyu) and domestic exclusivity (Sivelestat) demonstrates strong regulatory capabilities<\/li>\n\n\n\n<li><strong>Therapeutic Focus:<\/strong> Targeting high-prevalence chronic diseases aligns with China&#8217;s evolving healthcare needs and reimbursement priorities<\/li>\n\n\n\n<li><strong>Capital Markets Access:<\/strong> Hong Kong listing provides enhanced access to international capital and improved corporate governance standards<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-performance-amp-investment-outlook\">Financial Performance &amp; Investment Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>2025 Sales Achievement:<\/strong> RMB 686 million (USD 99.7 million) demonstrates solid commercial execution<\/li>\n\n\n\n<li><strong>Growth Trajectory:<\/strong> Revenue expected to accelerate as innovative pipeline candidates advance through clinical development<\/li>\n\n\n\n<li><strong>Market Opportunity:<\/strong> Positioned to benefit from China&#8217;s pharmaceutical innovation policies and increasing healthcare expenditure<\/li>\n\n\n\n<li><strong>Investment Thesis:<\/strong> Combines near-term revenue stability from established products with long-term optionality from innovative pipeline<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding Huilun Pharma&#8217;s business strategy, pipeline development, financial performance, and market opportunities. Actual results may differ materially due to risks including regulatory approvals, competitive dynamics, market adoption, and general economic conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/sehk26040203666_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of sehk26040203666_c.\"><\/object><a id=\"wp-block-file--media-c5d8de75-44d4-495b-9205-edf1664ff239\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/sehk26040203666_c.pdf\">sehk26040203666_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/sehk26040203666_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-c5d8de75-44d4-495b-9205-edf1664ff239\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Huilun Pharmaceutical Co., Ltd. has successfully completed its initial public offering (IPO) on the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[],"class_list":["post-62396","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shanghai Huilun Pharma Launches Hong Kong IPO with Integrated Pharmaceutical Platform and Robust Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Huilun Pharmaceutical Co., Ltd. has successfully completed its initial public offering (IPO) on the Hong Kong Stock Exchange, marking a significant milestone for the Chinese pharmaceutical company that operates an integrated, end-to-end pharmaceutical system spanning research and development, manufacturing, and commercialization.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62396\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shanghai Huilun Pharma Launches Hong Kong IPO with Integrated Pharmaceutical Platform and Robust Pipeline\" \/>\n<meta property=\"og:description\" content=\"Shanghai Huilun Pharmaceutical Co., Ltd. has successfully completed its initial public offering (IPO) on the Hong Kong Stock Exchange, marking a significant milestone for the Chinese pharmaceutical company that operates an integrated, end-to-end pharmaceutical system spanning research and development, manufacturing, and commercialization.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62396\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-04T14:04:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-04T14:04:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62396#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62396\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shanghai Huilun Pharma Launches Hong Kong IPO with Integrated Pharmaceutical Platform and Robust Pipeline\",\"datePublished\":\"2026-04-04T14:04:53+00:00\",\"dateModified\":\"2026-04-04T14:04:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62396\"},\"wordCount\":418,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62396#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62396\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62396\",\"name\":\"Shanghai Huilun Pharma Launches Hong Kong IPO with Integrated Pharmaceutical Platform and Robust Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-04T14:04:53+00:00\",\"dateModified\":\"2026-04-04T14:04:55+00:00\",\"description\":\"Shanghai Huilun Pharmaceutical Co., Ltd. has successfully completed its initial public offering (IPO) on the Hong Kong Stock Exchange, marking a significant milestone for the Chinese pharmaceutical company that operates an integrated, end-to-end pharmaceutical system spanning research and development, manufacturing, and commercialization.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62396#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62396\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62396#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shanghai Huilun Pharma Launches Hong Kong IPO with Integrated Pharmaceutical Platform and Robust Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shanghai Huilun Pharma Launches Hong Kong IPO with Integrated Pharmaceutical Platform and Robust Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Huilun Pharmaceutical Co., Ltd. has successfully completed its initial public offering (IPO) on the Hong Kong Stock Exchange, marking a significant milestone for the Chinese pharmaceutical company that operates an integrated, end-to-end pharmaceutical system spanning research and development, manufacturing, and commercialization.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62396","og_locale":"en_US","og_type":"article","og_title":"Shanghai Huilun Pharma Launches Hong Kong IPO with Integrated Pharmaceutical Platform and Robust Pipeline","og_description":"Shanghai Huilun Pharmaceutical Co., Ltd. has successfully completed its initial public offering (IPO) on the Hong Kong Stock Exchange, marking a significant milestone for the Chinese pharmaceutical company that operates an integrated, end-to-end pharmaceutical system spanning research and development, manufacturing, and commercialization.","og_url":"https:\/\/flcube.com\/?p=62396","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-04T14:04:53+00:00","article_modified_time":"2026-04-04T14:04:55+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62396#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62396"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shanghai Huilun Pharma Launches Hong Kong IPO with Integrated Pharmaceutical Platform and Robust Pipeline","datePublished":"2026-04-04T14:04:53+00:00","dateModified":"2026-04-04T14:04:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62396"},"wordCount":418,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62396#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62396","url":"https:\/\/flcube.com\/?p=62396","name":"Shanghai Huilun Pharma Launches Hong Kong IPO with Integrated Pharmaceutical Platform and Robust Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-04T14:04:53+00:00","dateModified":"2026-04-04T14:04:55+00:00","description":"Shanghai Huilun Pharmaceutical Co., Ltd. has successfully completed its initial public offering (IPO) on the Hong Kong Stock Exchange, marking a significant milestone for the Chinese pharmaceutical company that operates an integrated, end-to-end pharmaceutical system spanning research and development, manufacturing, and commercialization.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62396#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62396"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62396#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shanghai Huilun Pharma Launches Hong Kong IPO with Integrated Pharmaceutical Platform and Robust Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62396","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62396"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62396\/revisions"}],"predecessor-version":[{"id":62402,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62396\/revisions\/62402"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62396"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62396"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62396"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}